The advantages of the antituberculosis regimens which include Sinerdol-EH, a new tuberculostatic of rifampicin-type.
D000818:Animals; D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002675:Child, Preschool; D004285:Dogs; D006801:Humans; D007223:Infant; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D011817:Rabbits; D012293:Rifampin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; C039205:Sinerdol EH; D012293:Rifampin